Alberta Investment Management Corp Sells 10,000 Shares of Abivax SA Sponsored ADR $ABVX

Alberta Investment Management Corp trimmed its holdings in Abivax SA Sponsored ADR (NASDAQ:ABVX – Free Report) by 15.4% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 55,000 shares of the company’s stock after selling 10,000 shares during the quarter. Alberta Investment Management Corp’s holdings in Abivax were worth $5,446,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in ABVX. Hantz Financial Services Inc. lifted its position in Abivax by 22.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,296 shares of the company’s stock worth $128,000 after buying an additional 238 shares in the last quarter. Royce & Associates LP grew its holdings in Abivax by 35.8% during the 3rd quarter. Royce & Associates LP now owns 61,251 shares of the company’s stock worth $6,065,000 after acquiring an additional 16,148 shares during the last quarter. ACT Capital Partners L.P. bought a new stake in Abivax during the 3rd quarter worth about $8,417,000. Aberdeen Group plc grew its holdings in Abivax by 45.8% during the 3rd quarter. Aberdeen Group plc now owns 761,016 shares of the company’s stock worth $75,356,000 after acquiring an additional 238,991 shares during the last quarter. Finally, Nan Fung Trinity HK Ltd. increased its position in Abivax by 280.3% in the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 142,083 shares of the company’s stock valued at $14,069,000 after acquiring an additional 104,723 shares in the last quarter. 47.91% of the stock is owned by institutional investors.

Abivax Stock Down 4.5%

Shares of Abivax stock opened at $83.61 on Tuesday. The business has a fifty day simple moving average of $94.22 and a 200 day simple moving average of $112.38. The stock has a market cap of $7.32 billion, a PE ratio of -13.80 and a beta of 1.36. Abivax SA Sponsored ADR has a 12 month low of $69.81 and a 12 month high of $148.83.

Abivax (NASDAQ:ABVX – Get Free Report) last released its earnings results on Monday, September 21st. The company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.79). The business had revenue of $1.37 million during the quarter, compared to analysts’ expectations of $0.80 million. Analysts expect that Abivax SA Sponsored ADR will post -4.14 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on ABVX. Truist Financial dropped their target price on shares of Abivax from $155.00 to $151.00 and set a “buy” rating for the company in a research note on Tuesday, September 22nd. Piper Sandler reiterated an “overweight” rating on shares of Abivax in a research report on Wednesday, October 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a research note on Thursday, October 15th. Morgan Stanley reissued an “overweight” rating and issued a $180.00 price target on shares of Abivax in a report on Friday, July 24th. Finally, Barclays reissued an “overweight” rating and issued a $148.00 price target on shares of Abivax in a report on Tuesday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $155.00.

View Our Latest Stock Report on ABVX

Abivax Profile

(Free Report)

Abivax is a clinical-stage biopharmaceutical company headquartered in Paris, France. It develops treatments for chronic inflammatory diseases, with a focus on therapies that regulate the body’s immune response. The company’s lead candidate, obefazimod (formerly known as ABX464), is an oral small molecule being studied for ulcerative colitis and other inflammatory conditions. It is designed to increase production of miR-124, a molecule involved in regulating inflammation. Founded in 2013, Abivax conducts clinical development internationally.

Featured Stories

Want to see what other hedge funds are holding ABVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abivax SA Sponsored ADR (NASDAQ:ABVX – Free Report).

Institutional Ownership by Quarter for Abivax (NASDAQ:ABVX)

Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.